Boston, United States
Selux Diagnostics, Inc, with the slogan "Precision diagnostics for infectious disease," is a biotechnology startup founded in 2014 in the United States. The company is focused on developing a Next Generation Phenotyping (NGP) platform to revolutionize infectious disease patient treatment. This innovative platform aims to significantly enhance the speed and accuracy of personalized antibiotic therapies, ultimately leading to improved patient outcomes and a reduction in hospital-acquired infections.
The urgency of Selux's mission is underscored by the global threat of antibiotic resistance, as emphasized by the CDC. The current standard practice often involves overprescribing powerful, broad-spectrum antibiotics while awaiting diagnostic results, leading to prolonged and potentially ineffective treatments. Selux Diagnostics' NGP platform stands out as the only solution capable of delivering personalized therapy results within a day of hospital entry, expediting targeted treatment by up to 4 days for patients infected with multi-drug resistant organisms.
Notably, in September 25, 2018, SeLux announced a significant milestone-based contract worth up to $45 million with BARDA. This agreement includes an immediate $9.3 million disbursement for funding the clinical trial of the NGP platform. Additionally, a $25 million Series B financing round was secured to support the pivotal FDA trial for the NGP platform. Leading the round is Sands Capital Ventures, alongside returning investors RA Capital and Schooner Capital, as well as new investors Sands Capital and Northpond Ventures.
This vital support from prominent investors and government agencies underscores the confidence in Selux's innovative approach to combatting infectious disease, positioning the company for substantial impact and potential growth in the field of precision diagnostics.
